Navigation Links
Drug May Ease Cognitive Effects of Huntington's
Date:2/9/2010

Small study reports improvement in thinking skills,,

TUESDAY, Feb. 9 (HealthDay News) -- An experimental drug may improve thinking, learning and memory skills in people with Huntington's disease, an inherited neurodegenerative disorder, new research says.

Huntington's affects movement, behavior and cognitive abilities, and people with the disease usually die within 10 to 30 years of its onset. Cognitive problems begin early in the disease and increase as Huntington's progresses, leading to the inability to work or perform normal daily activities.

Currently, the only approved therapy for Huntington's is tetrabenazine, which treats movement problems but does not prevent cognitive decline or change the course of the disease.

In the new study, researchers assessed the safety and tolerability of a new drug with the proposed generic name latrepirdine, in people with mild to moderate Huntington's disease. The drug stabilizes and improves the function of mitochondria, parts of cells that help convert food into energy. Previous research has suggested that mitochondria abnormalities could play a role in Huntington's.

For 90 days, 46 people took 20 milligrams of latrepirdine three times a day, and 45 others took a placebo. The researchers said the drug was well-tolerated (87 percent of people taking latrepirdine completed the study, compared with 82 percent of the others), and the rates of adverse events were 70 percent in the treatment group, 80 percent in the placebo group.

The researchers also found that average scores on scales rating overall cognitive function improved in the treatment group and remained the same in the placebo group.

"Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well-tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," wrote Dr. Karl Kieburtz, of the School of Medicine and Dentistry at the University of Rochester in New York, and his colleagues.

"Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease," they added.

The study is published in the February issue of Archives of Neurology.

More information

We Move has more about Huntington's disease.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Feb. 8, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Hypertension may predict dementia in older adults with certain cognitive deficits
2. HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training.
3. New compound improves cognitive decline, symptoms of Alzheimers disease in rodents
4. First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains
5. Expert Panel Reaches Consensus on Our Ability to Improve Cognitive Health
6. Study finds significantly worse outcomes in cancer patients with cognitive impairment
7. Caffeine doesnt reverse the negative cognitive impact of alcohol, study shows
8. Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries
9. Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform
10. Diet, Cognitive Ability May Play Role in Heart Disease
11. HAPPYneuron Launches Beta Program for Innovative Cognitive Rehab Tools at AMIA Conference in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... 2016 , ... Brenton Engineering , powered by Pro ... wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new solution ... or fully-automatic case packing with a small footprint, rugged, highly flexible, and cost-effective ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
(Date:2/8/2016)... ... ... FileHold's document management software has been implemented by DocuSyst ... for FileHold software that is pay per user subscription-based and also does on-premise ... web services API. DocuSyst also advises clients on fully functioning back up technologies ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, PhD, ... healthcare companies can use newly released government data on populations and physicians to ... intervene and capture the value they create to succeed in new economic models ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... that the U.S. Food and Drug Administration (FDA) ... application for SB-318, a single treatment strategy intended ... I (MPS I). The SB-318 IND application is ... Phase 1/2 clinical study (SB-318-1502) designed to assess ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... Feb. 5, 2016 Amgen (NASDAQ: AMGN ) ... Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. ... David W. Meline , executive vice president and chief ... audio of the presentation can be accessed from the Events ... replay of the webcast will also be available on Amgen,s ...
Breaking Medicine Technology: